

**Enterprise P&T Meeting
Committee Meeting Minutes
April 29, 2024**

Voting Members Present

| | | | |
|--------------------------|-----------------------|-------------------------|----------------------|
| David Batluck, DO | Rogers Elebra, PharmD | Kelly Martin, PharmD | Jena Quinn, PharmD |
| Floyd (John) Brinley, MD | Fury Fecondo, PharmD | Michelle Murphy, PharmD | Christy Skibicki, MD |
| Kirt Caton, MD | Robert Hockmuth, MD | Eric Peters, PharmD | Loretta Sonnier, MD |
| Robert Clifford, MD | Emily Kryger, PharmD | Andrew Peterson, PharmD | Wayne Weart, PharmD |
| Donald Cooper, PharmD | Lenaye Lawyer, MD | David Petkash, MD | Rani Whitfield, MD |

Excused Voting Members

| | |
|----------------------|-------------------|
| Tracey Davis, PharmD | Yavar Moghimi, MD |
| Kendra Michael, MD | Kirby Smith, MD |

Invited Guests Present

| | | | |
|-----------------------------|--------------------------|-----------------------------|-------------------------|
| Christian Andreaggi, PharmD | Rajneel Farley, PharmD | Melissa Megrdochian, PharmD | Ally Seitz, PharmD |
| Bethany Baird, CPhT | Amanda Hunter, PharmD | Christopher Meny, RPh | Ruth Smith, PharmD |
| Linda Carreras, CPhT | Toks Kassim, PharmD | Patty Oaster | Mali Thomas, CPhT |
| Kathleen Clement | Jeffrey Kreitman, PharmD | Sarah Pawlak, PharmD | Lauren Washington, CPhT |
| Mike Colvin, PharmD | Natasha McGowan | Jeanine Plante, PharmD | Erich Weiss, PharmD |
| Patrick DeHoratius, PharmD | Lauren Megargell, PharmD | Alishia Richie, MD | Arlene Wiseman, PharmD |

| Issue | Discussion | Conclusion/Results | Action/ Person Responsible |
|--|---|---|--|
| 1. Call to Order | <p>The meeting was called to order at 6:02 PM EST.</p> <p>Welcomed all external and internal participants.</p> | Informational Only | Lenaye Lawyer |
| 2. Conflict of Interest Disclosure | No conflicts announced | Informational Only | Jeffrey Kreitman |
| 3. [REDACTED] | | [REDACTED] | [REDACTED] |
| 4. Review and approval of Feb. P&T and March Proxy Minutes | | Informational Only | Jeffrey Kreitman |
| 5. Old Business | | | |
| Relyvrio | <p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|------------------------|-------------------|-------------------|-------------------|
| | <p>[REDACTED]</p> | | |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |
| <p>6. New Business</p> | | | |

Aduhelm

PerformRx makes the following recommendations:

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED] /CHC:

Committee approved as recommended:

Motion: Kirt Caton
Second: Robert Hockmuth

PerformRx will update the criteria and formulary/PDL with any changes

| | | | |
|---------|---|---|--|
| | <ul style="list-style-type: none"> Retire the Aduhelm prior authorization criteria as the manufacturer is halting sales and development of Aduhelm. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] [REDACTED] | | |
| Leqembi | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p> <p>Comment: David Petkash made remarks on Leqembi – how much use are we seeing and are neurologists prescribing? Medicaid has minimal use of Leqembi through Pharmacy. Jeff stated will circle back with additional information.</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|-------------------|---|---|--|
| | <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none"> • Remove the requirement that approvals must be done by a Medical Director. • Streamline coverage duration section. <p>█ [REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] | | |
| Myasthenia Gravis | <p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█ [REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|--|--|--|--|
| | <p>█ [REDACTED] █ [REDACTED] █ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED]</p> <p>█ [REDACTED]</p> <p>█ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED]</p> <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Add newly approved Zilbrysq to the drug list and criteria.• Streamline language regarding requirements for meningococcal vaccinations. <p>█ [REDACTED]</p> | | |
|--|--|--|--|

| | | | |
|---|--|---|--|
| | <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] | | |
| Transthyretin-mediated Amyloidosis Agents | <p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

[REDACTED]/CHC:

- Add newly approved Wainua to the drug list and criteria as a preferred agent.
- Remove the genetic test requirement for Vyndaqel and Vyndamax.

[REDACTED]

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

| | | | |
|-----------------------------|-------------------|-------------------|-------------------|
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |
| <p>7. Drug Reviews</p> | | | |
| <p>A. Therapeutic Class</p> | | | |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |

| | PerformRx makes the following recommendations: | Committee approved as recommended: | No Changes |
|---------------------------------|---|---|---|
| Contraceptives - Foams, Devices | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">• No changes <p>[REDACTED]</p> | Motion: Wayne Weart Second: Andrew Peterson | |
| [REDACTED] | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> |

| | | | |
|---------------------------|--|---|--|
| | <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] | | |
| B. Single Products | | | |
| Provenge with PA Criteria | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] <p>[REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|---------|--|---|------------|
| | <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] ■ [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none"> • No changes to the formulary status of Provence® (sipuleucel-T). • Approve the Dendritic Cell Tumor Peptide Immunotherapy prior authorization with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] ■ [REDACTED] [REDACTED] [REDACTED] | | |
| Ridaura | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] [REDACTED] <p>[REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | No Changes |

| | | | |
|---------------------------|---|---|--|
| | <ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none"> • No change to the formulary status of Ridaura (auranofin). <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] | | |
| Filsuvez with PA Criteria | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

[REDACTED]/CHC:

- Add Filsuvez (birch triterpenes) to Tier 4 with a prior authorization requirement.
- Update the Vyjuvek (beremagene geperpavec-svdt) prior authorization criteria.
- Update title from Vyjuvek (beremagene geperpavec-svdt) to Epidermolysis Bullosa Agents.
- Add Filsuvez (birch triterpenes) to the drug list.
- Update initial coverage duration period to 2 months to align with wound closure assessment timepoints in the clinical trials.
- Update indication information to align with both listed products.
- Add product specific maximum dosing information to the initial and re-authorization criteria.

- [REDACTED]
- [REDACTED]
- [REDACTED]

| | | | |
|-----------------------------------|---|--|--|
| | <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] | | |
| <p>Rezdiffra with PA Criteria</p> | <p>PerformRx makes the following recommendations:</p> <p>█/CHC:</p> <ul style="list-style-type: none"> • Add Rezdiffra to Tier 4 of the formulary with a prior authorization requirement. • Approve the newly developed Rezdiffra prior authorization criteria. <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> <p>Comment: Wayne Weart stated that Rezdiffra was approved based on only a 12month study. It was an accelerated approval and not a full approval by the FDA. The other class of drugs are being studied. PerformRx will be monitoring and bring any new developments.</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|----------------------------------|---|--|--|
| | <p>[REDACTED]</p> <ul style="list-style-type: none"> ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] | | |
| <p>Amtagvi with PA Criteria.</p> | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] ▪ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

- [REDACTED]/CHC:
- Add Amtagvi to Tier 4 with a prior authorization requirement.
 - Approve ethe newly developed Amtagvi prior authorization criteria.

[REDACTED]
[REDACTED]
[REDACTED]

| | | | |
|---------------------------------|---|---|--|
| <p>Sucraid</p> | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none"> • No changes to the formulary status of Sucraid (sacrosidase). <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>No Changes</p> |
| <p>Adzynma with PA Criteria</p> | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

- [REDACTED]
[REDACTED]
[REDACTED]
- [REDACTED]
[REDACTED]

[REDACTED]
■ [REDACTED]
[REDACTED]

[REDACTED]
■ [REDACTED]
[REDACTED]

[REDACTED]
■ [REDACTED]
[REDACTED]
■ [REDACTED]
[REDACTED]

[REDACTED]
■ [REDACTED]
[REDACTED]
■ [REDACTED]
[REDACTED]

[REDACTED] **/CHC:**

- Add Adzynma to Tier 4 with a prior authorization requirement.
- Approve the newly developed Adzynma prior authorization criteria.

[REDACTED]

| | | | |
|---------------------------|---|---|--|
| | <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] | | |
| Eohilia with PA Criteria. | <p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|---------------------------|---|---|--|
| | <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED] | | |
| Fabhalta with PA Criteria | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Alishia Richie Second: Robert Hockmuth</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|------------------------|--|---|--|
| | <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED][REDACTED] | | |
| <p>8. New Products</p> | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>Add to the formulary for [REDACTED] [REDACTED]/CHC.</p> <ul style="list-style-type: none">• Penbraya <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <p>[REDACTED]:</p> | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

Natriuretic Peptides for
Achondroplasia (Voxzogo)

PerformRx makes the following
recommendations:

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

Committee approved as
recommended:

Motion: Donald Cooper
Second: Alishia Richie

PerformRx will
update the criteria
and formulary/PDL
with any changes

| | | | |
|-------------------|--|---|--|
| | <p>[REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">• Update the language to baseline growth velocity due to the age expansion population not having to meeting a minimum height velocity for inclusion in the trial. <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] | | |
| <p>[REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED] [REDACTED] [REDACTED] [REDACTED]</p> |

| | | | |
|-------------------------------------|--|---|--|
| | <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED] | | |
| Peanut Allergy Immunotherapy Agents | <p>PerformRx makes the following recommendations:</p> <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED] <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Exclude the concomitant use of Palforzia and Xolair. | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|------------|--|---|---|
| | <ul style="list-style-type: none">• Add language for initial and re-authorizations to be approved for all strengths and dosage forms of Palforzia. <p>[Redacted]</p> | | |
| [Redacted] | <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> | <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> | <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> |
| [Redacted] | <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> | <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> | <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p> |

| | | | |
|----------------------|--|---|--|
| | <ul style="list-style-type: none">■ [REDACTED][REDACTED][REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED][REDACTED]■ [REDACTED][REDACTED][REDACTED][REDACTED] | | |
| Somatostatin Analogs | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED][REDACTED][REDACTED][REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED][REDACTED][REDACTED][REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED][REDACTED][REDACTED][REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>PerformRx will update the criteria and formulary/PDL with any changes</p> |

| | | | |
|-------------------|---|-------------------|-------------------|
| | <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Somatostatin Analogs and Growth Hormone Receptor Antagonists prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] | | |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |

| | | | |
|--|--|---|---|
| <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> |
| <p>B. Prior Authorization Criteria Annual Review without Clinical Changes:</p> | | | |
| <p>Diagnosis Code Requirement</p> | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none"> • Approve the Diagnosis Code Requirement prior authorization criteria with no changes. <p>[REDACTED]</p> <ul style="list-style-type: none"> [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |

| Off-Label Uses Criteria | PerformRx makes the following recommendations: | Committee approved as recommended: | No Changes |
|-------------------------------------|--|---|-------------------|
| <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none"> • Approve the Off-Label Uses prior authorization criteria with no changes. <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>Motion: Donald Cooper Second: Alishia Richie</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> |

| | | | |
|--|--|---|-------------------|
| | <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] | | |
| Antisense Oligonucleotides for Duchenne Muscular Dystrophy | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |

| | | | |
|-------------------------------------|---|---|-------------------|
| | <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Atovaquone Suspension prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] | | |
| <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> |

| | | | |
|----------|--|---|-------------------|
| | <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] | | |
| Blincyto | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] <p>[REDACTED]</p> | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |

| | | | |
|-------------------|--|---|-------------------|
| | <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Blincyto prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] | | |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> |

| | | | |
|----------|---|---|------------|
| | <ul style="list-style-type: none">█ [REDACTED] | | |
| Filspari | <p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█/CHC:</p> <ul style="list-style-type: none">• Approve the Filspari prior authorization criteria with no clinical changes. | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | No Changes |

| | | | |
|---|---|---|-------------------|
| | <p>• [REDACTED] [REDACTED] [REDACTED]</p> | | |
| <p>Hydroxyprogesterone caproate (generic Delalutin)</p> | <p>PerformRx makes the following recommendations:</p> <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] [REDACTED] [REDACTED] [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">[REDACTED] [REDACTED] [REDACTED] [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |

| | | | |
|-------------------------------------|---|---|-------------------|
| | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Hydroxyprogesterone caproate (generic Delalutin) prior authorization criteria with no clinical changes. <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] | | |
| <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> |

| | | | |
|------------|--|---|------------|
| | <ul style="list-style-type: none">█ [REDACTED] | | |
| [REDACTED] | <ul style="list-style-type: none">█ [REDACTED] | [REDACTED] | [REDACTED] |
| Jesduvroq | PerformRx makes the following recommendations: █ [REDACTED] | Committee approved as recommended: Motion: Donald Cooper | No Changes |

Second: Alishia Richie

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

█ [REDACTED] /CHC:
• Approve the Jesdubroq prior authorization criteria with no clinical changes.

█ [REDACTED]
█ [REDACTED]
█ [REDACTED]
█ [REDACTED]

Ketamine

PerformRx makes the following recommendations:

Committee approved as recommended:

No Changes

Motion: Donald Cooper
Second: Alishia Richie

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]

- [REDACTED]/CHC:
- Approve the Ketamine prior authorization criteria with no clinical changes.

[REDACTED]

| | | | |
|---------|---|---|------------|
| | <ul style="list-style-type: none"> ████████████████████ ████████████████████ ████████ | | |
| Kuvan | <p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none"> ████████ <ul style="list-style-type: none"> ████████████████████ ████████████████████ ████████ ████████ <ul style="list-style-type: none"> ████████████████████ ████████████████████ ████████ ████████ <ul style="list-style-type: none"> ████████████████████ ████████████████████ ████████ <p>████████/CHC:</p> <ul style="list-style-type: none"> • Approve the Kuvan prior authorization criteria with no clinical changes. <ul style="list-style-type: none"> ████████ <ul style="list-style-type: none"> ████████████████████ ████████████████████ ████████ | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | No Changes |
| Lamzede | <p>PerformRx makes the following recommendations:</p> | <p>Committee approved as recommended:</p> | |

| | | | |
|--|---|---|-------------------|
| | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">• Approve the Lamzede prior authorization criteria with no clinical changes. <p>[REDACTED]</p> | <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |
|--|---|---|-------------------|

| Linezolid (Zyvox) | PerformRx makes the following recommendations: | Committee approved as recommended: | No Changes |
|-------------------|--|---|------------|
| [Redacted] | [Redacted] /CHC: <ul style="list-style-type: none">Approve the linezolid (Zyvox) prior authorization criteria with no clinical changes. [Redacted] | Motion: Donald Cooper Second: Alishia Richie [Redacted] | [Redacted] |

| | | | |
|--------|---|---|------------|
| | <p>[Redacted text]</p> | | |
| Multaq | <p>PerformRx makes the following recommendations:</p> <p>[Redacted text]</p> <p>[Redacted text]</p> <p>[Redacted text]</p> <p>[Redacted text]</p> <p>[Redacted text]</p> <p>[Redacted text]</p> | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | No Changes |

| | | | |
|-------------------|---|-------------------|-------------------|
| | <ul style="list-style-type: none">• Approve the Multaq prior authorization criteria with no clinical changes. <p>[REDACTED]</p> | | |
| <p>[REDACTED]</p> | <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED]</p> | <p>[REDACTED]</p> | <p>[REDACTED]</p> |

Palynziq

PerformRx makes the following recommendations:

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]/CHC:
• Approve the Palynziq prior authorization criteria with no clinical changes.

[REDACTED]

Committee approved as recommended:

Motion: Donald Cooper
Second: Alishia Richie

No Changes

Primary HLH Agents

PerformRx makes the following recommendations:

Committee approved as recommended:

No Changes

[Redacted]

Motion: Donald Cooper
Second: Alishia Richie

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

| | | | |
|----------|---|---|------------|
| | <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█/CHC:</p> <ul style="list-style-type: none"> • Approve the Primary Hemophagocytic Lymphohistiocytosis (HLH) Agents prior authorization criteria with no clinical changes. <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] █ [REDACTED] | | |
| Radicava | <p>PerformRx makes the following recommendations:</p> <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█</p> <ul style="list-style-type: none"> █ [REDACTED] █ [REDACTED] █ [REDACTED] <p>█</p> | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | No Changes |

| | | | |
|--------------|---|--------------|--------------|
| | <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] <p>█ [REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the Radicava prior authorization criteria with no clinical changes. <p>█ [REDACTED]</p> <ul style="list-style-type: none">█ [REDACTED]█ [REDACTED]█ [REDACTED] | | |
| █ [REDACTED] | █ [REDACTED] | █ [REDACTED] | █ [REDACTED] |

| | | | |
|--------------------------------|--|---|-------------------|
| | <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] | | |
| Topical mTOR Kinase Inhibitors | <p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED] <p>■/CHC:</p> <ul style="list-style-type: none">• Approve the Topical mTOR Kinase Inhibitors prior authorization criteria with no clinical changes. | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |

| | | | |
|---|---|---|-------------------|
| | <ul style="list-style-type: none">■ [REDACTED] | | |
| Treatments for Plasminogen Deficiency Type 1 (Ryplazim) | <p>PerformRx makes the following recommendations:</p> <ul style="list-style-type: none">■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED]■ [REDACTED] | <p>Committee approved as recommended:</p> <p>Motion: Donald Cooper Second: Alishia Richie</p> | <p>No Changes</p> |

| | | | |
|----------------------------------|--|---|-------------------|
| | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">• Approve the Treatments for Plasminogen Deficiency Type 1 (PLD1) prior authorization criteria with no clinical changes.• [REDACTED] <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] | | |
| <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED]</p> |
| <p>[REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED]</p> <ul style="list-style-type: none">• [REDACTED] <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED]</p> |
| <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED] [REDACTED]</p> | <p>[REDACTED]</p> |

| | | | |
|-----------------|---|-------------------------------------|---------------|
| | <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> | <p>[REDACTED]</p> <p>[REDACTED]</p> | |
| 10. Recalls | <p>1/30/2024 – 4/17/2024</p> <p>There were no Class 1 or 2 recalls impacting all lots for medications listed within Medispan.</p> | Informational | PerformRx |
| 11. Adjournment | The meeting adjourned at 7:07 PM EST | | Lenaye Lawyer |
| | The next meeting July 29th, 2024 6:00pm- 8:00pm EST | | |

Jeffrey Phillip Pham

7/29/24
Date